23:39 , Jan 18, 2019 |  BC Extra  |  Clinical News

AbbVie's Imbruvica misses pancreatic cancer endpoints

AbbVie Inc. (NYSE:ABBV) said late Friday Imbruvica ibrutinib missed the co-primary endpoints in the Phase III RESOLVE (PCYC-1137) trial as part of a first-line combination treatment of metastatic pancreatic cancer. In 424 patients, the Bruton's...
20:32 , Jan 18, 2019 |  BC Week In Review  |  Clinical News

BeiGene's BTK inhibitor gets U.S. breakthrough designation

BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160) said FDA granted breakthrough therapy designation to zanubrutinib (BGB-3111) to treat second-line mantle cell lymphoma (MCL). BeiGene President and General Manager of China Xiaobing Wu told BioCentury zanubrutinib is the first...
23:20 , Jan 14, 2019 |  BC Extra  |  Company News

BeiGene's Btk inhibitor gets U.S. breakthrough designation

BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160) said FDA granted breakthrough therapy designation to zanubrutinib (BGB-3111) to treat second-line mantle cell lymphoma (MCL). BeiGene President and General Manager of China Xiaobing Wu told BioCentury zanubrutinib is the first...
01:03 , Jan 12, 2019 |  BioCentury  |  Finance

Warning: cash needed

A near decade-long run of cheap money appears to be coming to a close, and most of the biotech sector isn’t well positioned for the new reality. BioCentury’s analysis shows that two-thirds of biotech companies...
17:38 , Jan 11, 2019 |  BC Week In Review  |  Company News

Second big M&A deal of 2019: Lilly to acquire Loxo

Eli Lilly and Co. (NYSE:LLY) said on Jan. 7 it reached an $8 billion agreement to acquire Loxo Oncology Inc. (NASDAQ:LOXO), the pharma's third cancer-focused acquisition in the past year. The deal also comes in...
17:32 , Jan 11, 2019 |  BC Week In Review  |  Financial News

InnoCare raises $160M to advance Btk inhibitor

InnoCare Pharma Ltd. (Beijing, China) said on Jan. 4 that it raised $160 million in a venture round led by Loyal Valley Capital with participation from 3H Health Investment, Epiphron Capital Fund II and existing...
15:12 , Jan 7, 2019 |  BC Extra  |  Company News

Second big M&A deal of 2019: Lilly to acquire Loxo

Eli Lilly and Co. (NYSE:LLY) has reached an $8 billion agreement to acquire Loxo Oncology Inc. (NASDAQ:LOXO), the pharma's third cancer-focused acquisition in the past year. The deal also comes in the wake of the...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
22:20 , Jan 4, 2019 |  BC Extra  |  Financial News

InnoCare raises $160M to advance Btk inhibitor

InnoCare Pharma Ltd. (Beijing, China) said Friday that it raised $160 million in a venture round led by Loyal Valley Capital with participation from 3H Health Investment, Epiphron Capital Fund II and existing investors Vivo...
19:02 , Jan 4, 2019 |  BC Week In Review  |  Company News

BMS deal weighs on Celgene partners

The proposed acquisition of Celgene Corp. (NASDAQ:CELG) by Bristol-Myers Squibb Co. (NYSE:BMY) on Jan. 3 put pressure on shares of Celgene partners Acceleron Pharma Inc. (NASDAQ:XLRN) and BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160) on a day when...